'» O'Neil supports this suggestion: «I've been working in oncology for more than 15 years,» she says, «I feel like we've been making progress in the last few years,
especially with immunotherapy.»
Not exact matches
At Thursday's Winship symposium on cancer
immunotherapy, Rafi said the name of the game is now combinations,
with an
especially good one being PD - 1 inhibitors plus IL2.
Although this benefit has not been seen in all patients treated
with immunotherapy, one of the goals of the CCIR is to improve our understanding of the immune system,
especially in the context of the tumor immune microenvironment, in order to modulate immunity to optimally enhance patient outcome.
Lead author Dr Nadia Guerrafrom the Department of Life Sciences at Imperial, said: «
Immunotherapies have shown unprecedented successes in treating cancer patients
with advanced forms of cancer,
especially metastatic melanomas.
Allogeneic cell therapies from primary cells for
immunotherapy applications are
especially challenging because of the vigor
with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.